Ferrer Internacional S.A. clinical trials

The registry lists 48 studies whose lead sponsor is Ferrer Internacional S.A. or one of 2 companies grouped under it. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2025.

Studies

Recruiting first, then most recently updated. Showing 48 of 48.

• Treprostinil in Newborns With Pulmonary Hypertension; a Non-Interventional Study to Collect Data on Drug Utilization, Safety, and EffectivenessRecruitingNCT06499363
• Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung DiseaseAvailableNCT05572996
• Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I DisorderSuspendedNCT03513549

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted after Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF EpisodesTerminatedNCT05979415Phase 2

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted after Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)Active, not recruitingNCT06355531Phase 2
• Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting SyndromeCompletedNCT04645953Phase 2

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted after Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral SclerosisCompletedNCT05178810Phase 3
• Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral SclerosisTerminatedNCT05866926Phase 3
• Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With ImpetigoCompletedNCT02090764Phase 3
• Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord InjuryStatus unknownNCT02917291Phase 1/2
• Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's DiseaseCompletedNCT04157933Phase 1

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted after Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Clinical Trial in Children Between 3 Months and 14 Years Old to Evaluate the Efficacy and Safety of Gelatin Tannate in the Treatment of Acute Diarrhea (INDIGO)CompletedNCT04065529Phase 3
• Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital SettingCompletedNCT02525991Phase 4
• Staccato® Granisetron Multiple Dose PKCompletedNCT04327765Phase 1

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted after Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Staccato Apomorphine Single and Multi Dose PKCompletedNCT03822364Phase 1

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted after Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Staccato Loxapine Pulmonary Safety in Healthy VolunteersCompletedNCT00789360Phase 1

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Staccato Prochlorperazine Thorough QT/QTcCompletedNCT00543062Phase 1

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Staccato Loxapine Single Dose PKCompletedNCT00444028Phase 1

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Staccato Prochlorperazine in Migraine (Out Patient)CompletedNCT00422812Phase 2

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Staccato Prochlorperazine in Migraine (in Clinic)CompletedNCT00610428Phase 2

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Staccato Loxapine in Agitation (Proof of Concept)CompletedNCT00369577Phase 2

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• ADASUVE-Lorazepam Drug-Drug InteractionCompletedNCT01877642Phase 4

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Prediction of Recurrent Pregnancy Loss by a New Thrombophilia Based Genetic Risk ScoreCompletedNCT03336463

  Sponsor listed in the registry: Ferrer inCode, S.L. · First submitted before Ferrer inCode, S.L. left Ferrer Internacional S.A.

• ADASUVE 2-dose Thorough QT/QTc StudyCompletedNCT01854710Phase 4

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Staccato Loxapine in Agitated Patients With SchizophreniaCompletedNCT00628589Phase 3

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Staccato Loxapine in Agitated Patients With Bipolar DisorderCompletedNCT00721955Phase 3

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Staccato Loxapine in Migraine (in Clinic)CompletedNCT00489476Phase 2

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Staccato Alprazolam in Panic AttackCompletedNCT00477451Phase 2

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Staccato Loxapine in Migraine (Out Patient)CompletedNCT00825500Phase 2

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to MonotherapyStatus unknownNCT02791958Phase 2
• Staccato Loxapine PK in Smokers and NonsmokersCompletedNCT00873769Phase 1

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Staccato Fentanyl Single and Multidose PKCompletedNCT00402350Phase 1

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Staccato Loxapine Multidose PKCompletedNCT00555412Phase 1

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Staccato Loxapine Pulmonary Safety in Patients With AsthmaCompletedNCT00890175Phase 1

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Staccato Zaleplon Single Dose PharmacokineticsCompletedNCT00620620Phase 1

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Staccato Alprazolam Single Dose PKCompletedNCT00444522Phase 1

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Staccato Loxapine Pulmonary Safety in Patients With COPDCompletedNCT00889837Phase 1

  Sponsor listed in the registry: Alexza Pharmaceuticals, Inc. · First submitted before Alexza Pharmaceuticals, Inc. became part of Ferrer Internacional S.A.

• Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With ImpetigoCompletedNCT01397461Phase 3
• Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension.CompletedNCT00334386Phase 4
• Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) TreatmentCompletedNCT01144286Phase 2
• Single Dose Study to Compare the Pharmacodynamics of Torasemide-PR 10 mg,Torasemide-IR 10 mg and Furosemide-IR 40 mg in Patients With Compensated Heart FailureTerminatedNCT01549158Phase 4
• Pharmacodynamic Clinical Trial of Cardiovascular Polypill on LDL CholesterolTerminatedNCT01362218Phase 2
• A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Low Density Lipoprotein (LDL) CholesterolTerminatedNCT01004705Phase 2
• A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood PressureTerminatedNCT01005290Phase 2
• Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in ChildrenTerminatedNCT01646580Phase 4
• ICTUS Study: International Citicoline Trial on Acute StrokeTerminatedNCT00331890Phase 3
• Study to Assess the Efficacy and Safety of GF-001001-00 Cream in Secondarily-Infected Traumatic LesionsCompletedNCT01005771Phase 2
• Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.CompletedNCT00409942Phase 4